The Only Treatment Alternative Left for a Patient Diagnosed with Advanced

Multiple Choice

The only treatment alternative left for a patient diagnosed with advanced cancer is a rare, highly experimental bone marrow transfusion with a 10% success rate. The insurance company refuses to authorize payment for the $200,000 procedure, arguing that the money could be better spent providing well-baby screening for 2,000 residents in the service area. What does this decision by the insurance company reflect?

A) Unethical conduct
B) Maleficence
C) Paternalism
D) Utility